SMMT - Summit Therapeutics plc
| Previous Close | 13.96 |
| Open | 14.08 |
| Bid | 13.60 x 1000 |
| Ask | 14.32 x 800 |
| Day's Range | 13.70 - 14.20 |
| 52 Week Range | 8.80 - 16.86 |
| Volume | 46,400 |
| Avg. Volume | 38,972 |
| Market Cap | 220.919M |
| Beta | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.63 |
- GlobeNewswire•27 days ago
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018-- Summit Therapeutics plc announces it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea in a ...
- GlobeNewswire•27 days ago
Award of Share Options and Restricted Stock Units
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018-- Summit Therapeutics plc, announces that the following options over new ordinary shares of one penny nominal value were granted on 20 April ...
- GlobeNewswire•last month
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018-- Summit Therapeutics ...
- GlobeNewswire•last month
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
Summit Therapeutics plc (SMMT) (SUMM.L) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week PhaseOut DMD clinical trial. “We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In the full trial results, we aim to see continued utrophin modulation and sustained changes in magnetic resonance parameters,” said Dr David Roblin, Chief Medical Officer and President of R&D of Summit.
- GlobeNewswire•last month
Recent Analysis Shows Honda Motor Co., Summit Therapeutics, Atlassian, Customers, Toyota Motor, and Adient Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 09, 2018-- Summit Therapeutics plc will announce its financial results for the fourth quarter and fiscal year ended 31 January 2018 on 11 April 2018.. ...
- GlobeNewswire•2 months ago
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018-- Summit Therapeutics plc announces that it has been selected for an Emerging Science dual oral and poster presentation at the 2018 American ...
- GlobeNewswire•2 months ago
Summit Therapeutics Announces Placement of £15.0 Million of Ordinary Shares
OXFORD, United Kingdom, March 27, 2018-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces the ...
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, InterDigital, Summit Therapeutics, and Kornit Digital — New Research Emphasizes Economic Growth
NEW YORK, March 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 14, 2018-- Summit Therapeutics plc highlighted the rigour being utilised in the collection and analysis of muscle biopsies and magnetic resonance spectroscopy ...
- GlobeNewswire•2 months ago
Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 13, 2018-- Summit Therapeutics plc announces the discovery of a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action. ...
- GlobeNewswire•2 months ago
Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of Ezutromid Allows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD, United ...
- GlobeNewswire•3 months ago
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle Health Data Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom, Feb. ...
- GlobeNewswire•3 months ago
Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference
OXFORD, United Kingdom, Feb. 23, 2018-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that management will ...
- ACCESSWIRE•5 months ago
Wired News – ESSA Announces Update on Previously Declared Equity Offering and Filing of Prospectus Supplement
Stock Monitor: Summit Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 19, 2017 / Active-Investors issued a free report on ESSA Pharma Inc. (NASDAQ: EPIX ), ("ESSA") which ...
Capital Cube•5 months agoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017
Categories: Yahoo FinanceGet free summary analysis Summit Therapeutics Plc reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Summit Therapeutics Plc – Arena Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Acer Therapeutics Inc. and Aviragen Therapeutics Inc (ARNA-US, SRPT-US, ACER-US and AVIR-US) that have also reported for this ... Read more (Read more...)